Wire · opportunities
'Practice-Changing' Data Expand Zanidatamab's Approval to Gastroesophageal Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 August 2026 · Fusion42 review
The FDA approved zanidatamab plus chemotherapy, with or without tislelizumab, as a first-line treatment for unresectable or metastatic HER2-positive gastroesophageal cancer, supported by phase III trial data showing significant survival improvements.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 25 Aug 2026 and 8 Sep 2026.
◆ ◆ The Wire takeaway
Your oncology biotech now needs to prioritise HER2 testing and consider integrating zanidatamab into treatment protocols for upper GI cancers as a regulatory green light widens patient eligibility.
◆ Coverage
10 sources · first reported 25 Aug 2026 · latest 8 Sep 2026
◆ Related on Wire
◆ Topics